Cellular Biomedicine Group, Inc. (CBMG) Financial Statements (2024 and earlier)

Company Profile

Business Address 209 PERRY PARKWAY
GAITHERSBURG, MD 20877
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13,58221,59715,44429,03639,71445,038
Cash and cash equivalents13,58221,59715,44429,03639,71445,038
Restricted cash and investments   17,000   
Receivables     (95)
Prepaid expense      
Intangible current assets 6,748  7,5227,8698,259
Other undisclosed current assets(5,354)1,9611,58611,65911,83511,832
Total current assets:14,97523,55834,03048,21659,41765,034
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization18,67019,280 14,29915,203 
Operating lease, right-of-use asset   20,106   
Property, plant and equipment22,44421,33821,43419,85619,99315,158
Long-term investments and receivables   240240240240
Long-term investments   240240240240
Intangible assets, net (including goodwill)7,6797,6797,6797,6797,67915,938
Goodwill7,6797,6797,6797,6797,6797,679
Intangible assets, net (excluding goodwill)      8,259
Other undisclosed noncurrent assets13,80014,03313,83515,16215,15624,969
Total noncurrent assets:62,59362,33063,29557,23658,27056,305
TOTAL ASSETS:77,56885,88897,324105,452117,687121,339
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,7274,0233,9717,1922,4392,792
Taxes payable303026292929
Employee-related liabilities 836     
Accounts payable1,5171,6202,0405,6861,352869
Accrued liabilities3432,3721,9051,4771,0581,894
Debt19,47514,00014,33414,13814,5466,132
Other liabilities5,7235,5095,3684,5275,1865,763
Other undisclosed current liabilities 528     
Total current liabilities:28,45223,53323,67325,85722,17214,687
Noncurrent Liabilities
Liabilities, other than long-term debt32,92917,20517,93412,54513,33914,142
Accounts payable and accrued liabilities 16,58417,205 12,54513,33914,142
Other liabilities16,345 17,934   
Other undisclosed noncurrent liabilities(16,345)     
Total noncurrent liabilities:16,58417,20517,93412,54513,33914,142
Total liabilities:45,03640,73741,60738,40235,51028,828
Equity
Equity, attributable to parent, including:32,53345,15155,71867,05082,17792,511
Common stock202020202020
Treasury stock, value (14,993)(14,993)(14,993)(14,993)(14,993)
Additional paid in capital274,405273,535272,118271,075270,034267,876
Accumulated other comprehensive loss(1,854)(1,898)(1,461)(1,772)(1,469)(1,073)
Accumulated deficit(225,046)(211,514)(199,967)(187,280)(171,416)(159,319)
Other undisclosed equity, attributable to parent(14,993)     
Total equity:32,53345,15155,71867,05082,17792,511
TOTAL LIABILITIES AND EQUITY:77,56885,88897,324105,452117,687121,339

Income Statement (P&L) ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Revenues1251,2282912621,26249
Operating lease, lease income1251,228 2621,262 
Cost of revenue  (54)  (8)
Gross profit:1251,2282362621,26241
Operating expenses(13,367)(11,431)(13,090)(16,492)(12,284)(9,466)
Other undisclosed operating income (loss)(125)(1,228)54(262)(1,262)8
Operating loss:(13,367)(11,431)(12,799)(16,492)(12,284)(9,417)
Nonoperating income (expense)(165)(115)11062718983
Other nonoperating income (expense)(188)(128)(68)2747(15)
Interest and debt expense   (161)  (40)
Loss from continuing operations before equity method investments, income taxes:(13,532)(11,546)(12,850)(15,864)(12,095)(9,374)
Other undisclosed income from continuing operations before income taxes   161  40
Loss from continuing operations before income taxes:(13,532)(11,546)(12,689)(15,864)(12,095)(9,334)
Income tax expense (benefit)  (2)20(1)(2)
Loss from continuing operations:(13,532)(11,547)(12,687)(15,864)(12,097)(9,337)
Loss before gain (loss) on sale of properties:(13,532)(11,547)(12,687)(15,864)(12,097)(9,337)
Net loss available to common stockholders, diluted:(13,532)(11,547)(12,687)(15,864)(12,097)(9,337)

Comprehensive Income ($ in thousands)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Net loss:(13,532)(11,547)(12,687)(15,864)(12,097)(9,337)
Other comprehensive income (loss)44(437)311(304)(396)396
Comprehensive loss, net of tax, attributable to parent:(13,488)(11,984)(12,375)(16,168)(12,492)(8,941)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: